Skip to Main Content
Try STAT+ TODAY
Trending:
Pharmalot
Coronavirus
Health
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

In the booming field of synthetic biology, a back-end business reinvents itself

  • Rebecca Robbins

By Rebecca Robbins Oct. 3, 2018

Reprints
Ginkgo Bioworks 02
A liquid-handling robot pipettes pieces of DNA at the Ginkgo Bioworks headquarters in Boston. Ruby Wallau/STAT

SAN FRANCISCO — They print DNA, design proteins, and sell pipetting robots — all the traditionally forgotten back-end technology supporting the drug developers that command the spotlight.

But these days, a once-sleepy industry has been reinvented as the booming field of synthetic biology.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Rebecca Robbins

Rebecca Robbins

Health Tech Correspondent

Rebecca covers health technology. She is the co-author of the newsletter STAT Health Tech.

Tags

A complicated fall vaccine campaign: Updated Covid boosters, flu…
A complicated fall vaccine campaign: Updated Covid boosters, flu shots, and how to time the jabs
Comparing the Pfizer and Moderna Covid vaccines for young…
Comparing the Pfizer and Moderna Covid vaccines for young children
‘Microdosing’ is touted by ’shroomers and Reddit users. Science…
‘Microdosing’ is touted by ’shroomers and Reddit users. Science is starting to test their claims —…
Pharmalittle: Activist investor targets Cardinal Health; 340B drug sales…
Pharmalittle: Activist investor targets Cardinal Health; 340B drug sales rose to $44 billion last year
Merck, a loser in the Covid vaccine race, reinvests…
Merck, a loser in the Covid vaccine race, reinvests in mRNA through a Cambridge startup
Clinical validation will save digital health’s reputation
Clinical validation will save digital health’s reputation

Recommended Stories